ECONOMIC EVALUATION OF TOPICAL ADMINISTRATION OF GEL WITH PIRFENIDONE (KITOSCELL Q®) AS AN ADJUVANT IN THE TREATMENT OF PATIENTS WITH DIABETIC FOOT ULCERS
Author(s)
Peña P1, Pineda R1, Figueroa A2, Lemus F2, Orozco D2, Flores B2
1Grupo Medifarma, S.A. de C.V., Ciudad de México, Mexico, 2Pharmamanagement EAS S de RL de CV, Cuidad de México, Mexico
OBJECTIVES: To evaluate the cost-effectiveness of the gel with Pirfenidone treatment as an adjuvant in patients with diabetic foot ulcers (DFU), compared to the alternatives available in the National Formulary (NF). METHODS: A decision-tree model was implemented to compare the costs and effectiveness of Pirfenidone versus the alternatives available in the NF (gauze, hydrocolloids and antimicrobials dressings) for the treatment of DFU. The clinical outcome was defined as full epithelialization and the time horizon was 8-weeks. Local costs of the resources were obtained from those published by the Mexican Institute of Social Security (IMSS), and the price of the Pirfenidone was provided by Grupo Medifarma. Univariate and probabilistic sensitivity analysis were performed to confirm the robustness of the model findings. The time horizon was 8-week. The analysis was done from public perspective. RESULTS: The use of Pirfenidone as adjuvant in the treatment of patients with DFU in a cohort of 100 patients is a cost-saving alternative, demonstrating an increase of 38.1% completely re-epithelialized ulcers in contrast to other dressings, for $44,318.43. CONCLUSIONS: Pirfenidone, is an alternative that provides health benefits use ad adjuvant in the treatment of patients with DFU; and in addition, represents savings to the public health system.
Conference/Value in Health Info
2017-05, ISPOR 2017, Boston, MA, USA
Value in Health, Vol. 20, No. 5 (May 2017)
Code
PMD63
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Diabetes/Endocrine/Metabolic Disorders